Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GW 572016

Known as: GW-572016, GW572016 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

lapatiniblapatinib ditosylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
Background: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
Highly Cited
2008
Highly Cited
2008
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2008
Highly Cited
2008
The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and…
Lapatinib [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Highly Cited
2006
Highly Cited
2006
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2005
Highly Cited
2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients…
PURPOSE This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Highly Cited
2005
Highly Cited
2005
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
PURPOSE This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients… Expand
Highly Cited
2005
Highly Cited
2005
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
Antibodies and small molecule tyrosine kinase inhibitors targeting ErbB2 exhibit distinct, noncross resistant mechanisms of… Expand
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2005
Highly Cited
2005
The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Effective treatment of estrogen receptor (ER)-positive breast cancers with tamoxifen is often curtailed by the development of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2004
Highly Cited
2004
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2002
Highly Cited
2002
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE